Stock Scan April 2018: Pharma's Fizz Falls Flat
Executive Summary
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.
You may also be interested in...
Takeda, Shire Finally Seal £46bn Deal
Persistence pays off for Takeda as it reaches a confirmed deal for the acquisition of Shire after a dogged pursuit, paving the way for the largest ever M&A transaction both in the Japanese pharma sector and by any Japanese company of an overseas target.
Stock Scan Q1 2018: A Slump And A Proper Correction
The story of the first quarter of 2018 is the impact of the general stock downturn at the end of January and the selective recovery that followed. But even though AbbVie and others had their own private yo-yos, the real correction took a while.
Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy
Data showing overall survival benefit for Keytruda in patients with at least 1% PD-L1 expression ups the ante for competitors Bristol and Roche, which will be presenting data for combinations in lung cancer at the American Association of Clinical Research meeting in April.